Clinical Focus

• Family Medicine

Professional Education

Community and International Work

• Mental health care and HIV prevention 

Current Research Interests

A pilot study integrating HIV prevention and care with treatment of psychological trauma in vulnerable Rwandan youth: A community-based pilot intervention. Collaboration between Stanford University and Rwanda NGO, Uyisenga N’Manzi.

Clinical Trials

• A5286: A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy Recruiting
• A5296: Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study Recruiting
• A5303: A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel, Maraviroc-containing Antiretroviral Regimen in Treatment-Na·ve Patients Infected with R5-tropic HIV-1 Recruiting
• ACTG 5298: A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men Recruiting
• Tobira 652-2-202: A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus Recruiting

Publications

• Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. AIDS. 2011; 25 (2): 211-20
• Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. Antimicrob Agents Chemother. 2010; 54 (6): 2473-9
• Switch from Enfuvirtide to Raltegravir in patients with indetectable viral load: Efficacy and safety at 24 weeks in a Montreal Cohort Annie Talbot, N Machouf, R Thomas, S Marcotte, R Therrien, B Lessard, S Dufresne, R Lalonde. JAIDS. 2009; 51 (3): 361-364
• Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. J Clin Virol. 2009; 46 (4): 305-8
• Acute renal failure in 4 HIV-Infected patients: potential association with Tenofovir and ARVs Suzanne Marcotte, A Talbot , B Trottier. Canadian Journal of Infectious Disease and Medical Microbiology. 2008; 19 (1): 75-76